Investment firms are showing increased activity in
Bio-Rad Laboratories, Inc..
Amundi, Caxton Associates LLP, Ariel Investments LLC, The Manufacturers Life Insurance Company, Jane Street Group LLC, and Wellington Management Group LLP have boosted their holdings in the bio-tech company. Despite
uncertainty in Bio-Rad's growth potential and a
drop in its value, some see the company as
undervalued due to its low debt.
Navigating challenges, the company focuses on its long-term value driven by its steady business and stake in Sartorius. Bio-Rad recently introduced new
Digital PCR Systems, an
innovation that prompted financial analysts to adjust their estimates. After a period of decline, Bio-Rad's Q2 2025 earnings showed a significant improvement, albeit with some inconsistencies. The firm reported a successful acquisition of
Stilla Technologies, potentially
reshaping the market with an expanded digital PCR portfolio. Views on Bio-Rad stock's fair value differ; some consider it
overvalued. The future of Bio-Rad Laboratories stock remains somewhat uncertain due to these varying factors.
Bio-Rad Laboratories Stocks News Analytics from Mon, 11 Nov 2024 08:00:00 GMT to Sat, 13 Sep 2025 09:57:02 GMT -
Rating 3
- Innovation 7
- Information 6
- Rumor 0
